GRI Bio, Inc. (GRI)
GRINASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.40
-0.0220 (-1.55%) today
At the close, Nov 16, 4:00 PM ET. Pre-market $1.41 +0.69%
- Market cap
- $3.08m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.36 to $64.12
- Average volume
- –
- Previous close
- $1.42
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $27.00, +1828.6% from here
Earnings
next estimate $-0.8300Next report
Mar 2026
-76.9%
Jun 2026
+24.2%
Sep 2026
+17.9%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$3.36m | -$2.66m | -$2.00m | -$1.65m |
| Net income | -$3.36m | -$2.66m | -$2.00m | -$1.64m |
News
8 latest- GRI Bio, Inc. Completes Patient Enrollment in Phase 2a Study of GRI-0621 for Idiopathic Pulmonary Fibrosis, Interim Results Show Safety and TolerabilityQuiver Quantitative · Jul 1, 2025
- GRI Bio, Inc. Reports Positive Interim Safety Results for GRI-0621 in Phase 2a Study for Idiopathic Pulmonary FibrosisQuiver Quantitative · Jun 26, 2025
- GRI Bio Reports Promising Preclinical Data for GRI-0621 in Treatment of Pulmonary Fibrosis at 2025 ATS ConferenceQuiver Quantitative · May 22, 2025
- GRI Bio, Inc. CEO Marc Hertz to Participate in Live Webcast Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase on May 21, 2025Quiver Quantitative · May 16, 2025
- GRI Bio, Inc. Reports Positive Phase 2a Interim Safety and Biomarker Results for GRI-0621 in Idiopathic Pulmonary Fibrosis TreatmentQuiver Quantitative · May 15, 2025
- GRI Bio, Inc. CEO Marc Hertz Discusses Advancements in NKT Cell Modulators for IPF in Recent Virtual Investor SegmentQuiver Quantitative · Mar 18, 2025
- GRI Bio, Inc. Anticipates Key Phase 2a Data Readouts for GRI-0621 in 2025 While Securing Cash Runway for OperationsQuiver Quantitative · Mar 17, 2025
- GRI Bio, Inc. Regains Compliance with Nasdaq Minimum Bid Price RuleQuiver Quantitative · Mar 11, 2025
The company
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of Natural Killer T ('NKT') cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT ('iNKT') cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- gribio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.